Evidence map›Paper›PMID 35661922›Full record

ArticleVirchows Archiv : an international journal of pathology2022

H3K27m3 overexpression as a new, BCL2 independent diagnostic tool in follicular and cutaneous follicle center lymphomas.

Magdalena M Brune, Visar Vela, Ivana Bratic Hench, Susanne Dertinger, Vanessa Borgmann, Stefan Dirnhofer, Alexandar Tzankov

Open access · hybridAbstract read
In one paragraph

Article in Virchows Archiv : an international journal of pathology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 3 countries.

Magdalena M BruneInstitute of Medical Genetics and Pathology, University Hospital Basel, University Basel, Schönbeinstrasse 40, CH-4031, Basel, Switzerland.
Visar VelaInstitute of Medical Genetics and Pathology, University Hospital Basel, University Basel, Schönbeinstrasse 40, CH-4031, Basel, Switzerland.
Ivana Bratic HenchInstitute of Medical Genetics and Pathology, University Hospital Basel, University Basel, Schönbeinstrasse 40, CH-4031, Basel, Switzerland.
Susanne DertingerInstitute of Pathology, Hospital Feldkirch, Feldkirch, Austria.
Vanessa BorgmannInstitute of Pathology and Neuropathology, Eberhard Karls University of Tübingen and Comprehensive Cancer Center, University Hospital Tübingen, Tübingen, Germany.
Stefan DirnhoferInstitute of Medical Genetics and Pathology, University Hospital Basel, University Basel, Schönbeinstrasse 40, CH-4031, Basel, Switzerland.
Alexandar TzankovInstitute of Medical Genetics and Pathology, University Hospital Basel, University Basel, Schönbeinstrasse 40, CH-4031, Basel, Switzerland. alexandar.tzankov@usb.ch.ORCID http://orcid.org/0000-0002-1100-3819
University Hospital of Basel · CHLandeskrankenhaus Feldkirch · ATUniversity of Tübingen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Approximately 15% of follicular lymphomas (FL) lack overexpression of BCL2 and the underlying translocation t(14;18). These cases can be diagnostically challenging, especially regarding follicular hyperplasia (FH). In a subset of FL, mutations in genes encoding for epigenetic modifiers, such as the histone-lysine N-methyltransferase EZH2 (enhancer of zeste homolog 2), were found, which might be used diagnostically. These molecular alterations can lead to an increased tri-methylation of histone H3 at position lysine 27 (H3K27m3) that, in turn, can be visualized immunohistochemically. The aim of this study was to analyze the expression of H3K27m3 in FL, primary cutaneous follicle center lymphomas (PCFCL), and pediatric-type FL (PTFL) in order to investigate its value in the differential diagnosis to FH and other B cell lymphomas and to correlate it to BCL2 expression and the presence of t(14;18). Additionally, the mutational profile of selected cases was considered to address H3K27m3's potential use as a surrogate parameter for mutations in genes encoding for epigenetic modifiers. Eighty-nine percent of FL and 100% of PCFCL cases overexpressed H3K27m3, independently of BCL2, EZH2, and the presence of mutations. In contrast, 95% of FH and 100% of PTFL cases lacked H3K27m3 overexpression. Other B cell lymphomas considered for differential diagnosis also showed overexpression of H3K27m3 in the majority of cases. In summary, overexpression of H3K27m3 can serve as a new, BCL2 independent marker in the differential diagnosis of FL and PCFCL, but not PTFL, to FH, while being not of help in the differential diagnosis of FL to other B cell lymphomas.

Indexed as

Lymphoma, B-CellLymphoma, FollicularChildEnhancer of Zeste Homolog 2 ProteinHistonesHumansLysineProto-Oncogene Proteins c-bcl-2BCL2 protein, humanEnhancer of Zeste Homolog 2 ProteinHistonesLysineProto-Oncogene Proteins c-bcl-2BCL2EZH2Follicular hyperplasiaFollicular lymphomaH3K27m3

Identifiers

PMID35661922
PMCPMC9485181
OpenAlexW4281639038

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.